Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;140(3):409-413.
doi: 10.1007/s00401-020-02188-w. Epub 2020 Jul 8.

CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas

Philipp Sievers #  1   2 , Thomas Hielscher #  3 , Daniel Schrimpf  1   2 , Damian Stichel  1   2 , David E Reuss  1   2 , Anna S Berghoff  4 , Marian C Neidert  5 , Hans-Georg Wirsching  6 , Christian Mawrin  7 , Ralf Ketter  8 , Werner Paulus  9 , Guido Reifenberger  10   11 , Katrin Lamszus  12 , Manfred Westphal  12 , Nima Etminan  13 , Miriam Ratliff  13 , Christel Herold-Mende  14 , Stefan M Pfister  15   16   17 , David T W Jones  15   18 , Michael Weller  6 , Patrick N Harter  19   20   21   22 , Wolfgang Wick  23   24 , Matthias Preusser  25 , Andreas von Deimling  1   2 , Felix Sahm  26   27   28
Affiliations

CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas

Philipp Sievers et al. Acta Neuropathol. 2020 Sep.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Time to progression or recurrence (TTP) of the 528 patients in the cohort stratified for CDKN2A/B homozygous deletion vs. WHO grade (a, b). Forest plot of univariable (unadjusted) hazard ratios for TTP for CDKN2A/B homozygous deletions stratified by WHO grade, methylation classes, TERT promoter mutation status, sex, age and location (c). AgeT gives age tertiles. IA p value gives p value for test on interaction, i.e., different prognostic effect of CDKN2A/B homozygous deletion in subgroups. MC methylation class, ben benign, int intermediate, mal malignant, F female, M male, TTP time to progression/recurrence
See this image and copyright information in PMC

References

    1. Bostrom J, Meyer-Puttlitz B, Wolter M, Blaschke B, Weber RG, Lichter P, et al. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol. 2001;159:661–669. doi: 10.1016/S0002-9440(10)61737-3. - DOI - PMC - PubMed
    1. Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555:469–474. doi: 10.1038/nature26000. - DOI - PMC - PubMed
    1. Goutagny S, Yang HW, Zucman-Rossi J, Chan J, Dreyfuss JM, Park PJ, et al. Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. Clin Cancer Res. 2010;16:4155–4164. doi: 10.1158/1078-0432.CCR-10-0891. - DOI - PubMed
    1. Guyot A, Duchesne M, Robert S, Lia AS, Derouault P, Scaon E, et al. Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma. J Neurooncol. 2019;145:449–459. doi: 10.1007/s11060-019-03333-6. - DOI - PubMed
    1. Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DT, et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol. 2013;126:907–915. doi: 10.1007/s00401-013-1195-5. - DOI - PubMed

Publication types

Substances

LinkOut - more resources